Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma

Baxter, M.A., Glen, H. and Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14(20), pp. 2021-2029. (doi: 10.2217/fon-2017-0689) (PMID:29783903)

159272.pdf - Accepted Version



Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases. Patients often present at an advanced stage when treatment options are limited. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been the first-line treatment in this setting for almost a decade. Several subsequent targeted therapies have failed to demonstrate significant improvement in survival. The results of the REFLECT study suggest that lenvatinib, a multikinase inhibitor, may have promised as a first-line treatment in patients with advanced HCC. This article will review the development of lenvatinib and the evidence behind its potential use in patients with advanced HCC.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Glen, Dr Hilary and Evans, Professor Jeff
Authors: Baxter, M.A., Glen, H., and Evans, T.R.J.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Future Oncology
Publisher:Future Medicine
ISSN (Online):1744-8301
Published Online:22 May 2018
Copyright Holders:Copyright © 2018 Future Medicine Ltd
First Published:First published in Future Oncology 14(20): 2021-2029
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record